Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 7/20 | 0.37 |
| ▸ | CTRC | Q99895 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765465 | 0.90 | LMNA (0.39) | CASP1LMNAELANEHPGDHTT | |
| SCHEMBL30765916 | 0.89 | CMA1 (0.41) | CASP1LMNAELANECMA1CTRC | |
| SCHEMBL30765805 | 0.87 | LMNA (0.39) | CASP1LMNAELANEHPGDKDM4E | |
| SCHEMBL30765547 | 0.87 | TDP1 (0.40) | CASP1LMNAELANEHPGDHSD17B10 | |
| SCHEMBL30765926 | 0.86 | GAA (0.52) | CASP1LMNAELANEHPGDHTT | |
| SCHEMBL30765947 | 0.85 | LMNA (0.40) | LMNAHPGDHTTHSD17B10HDAC6 | |
| SCHEMBL30765580 | 0.83 | ELANE (0.39) | LMNAELANEHPGDHTTHSD17B10 | |
| SCHEMBL30765548 | 0.83 | F2 (0.39) | CASP1ELANECMA1CTRCPOLB | |
| SCHEMBL30765778 | 0.82 | LMNA (0.37) | LMNAHPGDHTTHSD17B10HDAC6 | |
| SCHEMBL30765769 | 0.81 | NTRK1 (0.40) | CASP1ELANECMA1CTRCPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |